A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.

Trial Profile

A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs LIQ 001 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Acronyms LIfT
  • Sponsors Liquidia Technologies
  • Most Recent Events

    • 03 Jan 2011 Planned end date changed from 1 Nov 2011 to 1 Dec 2011 as reorted by ClinicalTrials.gov.
    • 03 Jan 2011 Actual initiation date changed from 6 Oct 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 03 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top